BRIEF-Allogene Therapeutics Selects Standard FC Regimen For Alpha3 Study - SEC Filing

Reuters

Aug 01

BRIEF-Allogene <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Selects Standard FC Regimen For Alpha3 Study - SEC Filing

Aug 1 (Reuters) - Allogene Therapeutics Inc ALLO.O:

ALLOGENE THERAPEUTICS INC - SELECTS STANDARD FC REGIMEN FOR ALPHA3 STUDY - SEC FILING
ALLOGENE THERAPEUTICS INC - FC PLUS ALLO-647 ARM CLOSED DUE TO ADVERSE EVENT - SEC FILING
ALLOGENE THERAPEUTICS INC: NONE OF CO'S TRIALS OPEN TO ENROLLMENT OR PIPELINE PROGRAMS INCLUDE ALLO-647
ALLOGENE THERAPEUTICS: WILL ADVANCE NEXT-GENERATION ALLOCAR T PRODUCT CANDIDATES USING PROPRIETARY DAGGER PLATFORM TECHNOLOGY
ALLOGENE THERAPEUTICS: GRADE 5 ADVERSE EVENT IN FC PLUS ALLO-647 ARM ATTRIBUTED TO USE OF ALLO-647

Source text: [ID:n0001193125-25-171091]

Further company coverage: ALLO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2556081151"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556081151\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556081151?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-01 21:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556081151","market":"us","top_or_hot":-1,"title":"BRIEF-Allogene Therapeutics Selects Standard FC Regimen For Alpha3 Study - SEC Filing","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Allogene <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Selects Standard FC Regimen For Alpha3 Study - SEC Filing</title></head><body><p><span>Aug 1 (Reuters)</span><span> - </span>Allogene Therapeutics Inc <span>ALLO.O</span>:</p><ul><li><p>ALLOGENE THERAPEUTICS INC - SELECTS STANDARD FC REGIMEN FOR ALPHA3 STUDY - SEC FILING</p></li><li><p>ALLOGENE THERAPEUTICS INC - FC PLUS ALLO-647 ARM CLOSED DUE TO ADVERSE EVENT - SEC FILING</p></li><li><p>ALLOGENE THERAPEUTICS INC: NONE OF CO'S TRIALS OPEN TO ENROLLMENT OR PIPELINE PROGRAMS INCLUDE ALLO-647</p></li><li><p>ALLOGENE THERAPEUTICS: WILL ADVANCE NEXT-GENERATION ALLOCAR T PRODUCT CANDIDATES USING PROPRIETARY DAGGER PLATFORM TECHNOLOGY</p></li><li><p>ALLOGENE THERAPEUTICS: GRADE 5 ADVERSE EVENT IN FC PLUS ALLO-647 ARM ATTRIBUTED TO USE OF ALLO-647</p></li></ul><p>Source text: [ID:n0001193125-25-171091]</p><p>Further company coverage: <span>ALLO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Allogene Therapeutics Selects Standard FC Regimen For Alpha3 Study - SEC Filing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Allogene Therapeutics Selects Standard FC Regimen For Alpha3 Study - SEC Filing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-01 21:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Allogene <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Selects Standard FC Regimen For Alpha3 Study - SEC Filing</title></head><body><p><span>Aug 1 (Reuters)</span><span> - </span>Allogene Therapeutics Inc <span>ALLO.O</span>:</p><ul><li><p>ALLOGENE THERAPEUTICS INC - SELECTS STANDARD FC REGIMEN FOR ALPHA3 STUDY - SEC FILING</p></li><li><p>ALLOGENE THERAPEUTICS INC - FC PLUS ALLO-647 ARM CLOSED DUE TO ADVERSE EVENT - SEC FILING</p></li><li><p>ALLOGENE THERAPEUTICS INC: NONE OF CO'S TRIALS OPEN TO ENROLLMENT OR PIPELINE PROGRAMS INCLUDE ALLO-647</p></li><li><p>ALLOGENE THERAPEUTICS: WILL ADVANCE NEXT-GENERATION ALLOCAR T PRODUCT CANDIDATES USING PROPRIETARY DAGGER PLATFORM TECHNOLOGY</p></li><li><p>ALLOGENE THERAPEUTICS: GRADE 5 ADVERSE EVENT IN FC PLUS ALLO-647 ARM ATTRIBUTED TO USE OF ALLO-647</p></li></ul><p>Source text: [ID:n0001193125-25-171091]</p><p>Further company coverage: <span>ALLO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nFWN3TT1DF:1","article_id":"2556081151","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556081151","pubTimestamp":1754056490,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Allogene Therapeutics Selects Standard FC Regimen For Alpha3 Study - SEC FilingAug 1  - Allogene Therapeutics Inc ALLO.O:ALLOGENE THERAPEUTICS INC - SELECTS STANDARD FC REGIMEN FOR ALPHA3 STUDY - SEC FILINGALLOGENE THERAPEUTICS INC - FC PLUS ALLO-647 ARM CLOSED DUE TO ADVERSE EVENT - SEC FILINGALLOGENE THERAPEUTICS INC: NONE OF CO'S TRIALS OPEN TO ENROLLMENT OR PIPELINE PROGRAMS INCLUDE ALLO-647ALLOGENE THERAPEUTICS: WILL ADVANCE NEXT-GENERATION ALLOCAR T PRODUCT CANDIDATES USING PROPRIETARY DAGGER PLATFORM TECHNOLOGYALLOGENE THERAPEUTICS: GRADE 5 ADVERSE EVENT IN FC PLUS ALLO-647 ARM ATTRIBUTED TO USE OF ALLO-647Source text: [ID:n0001193125-25-171091]Further company coverage: ALLO.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BK4139":"生物科技","ALLO":"Allogene Therapeutics Inc."},"translate_title":"简介-Allogene Therapeutics为Alpha3研究选择标准FC方案-SEC备案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALLO":0.9},"content_text":"BRIEF-Allogene Therapeutics Selects Standard FC Regimen For Alpha3 Study - SEC FilingAug 1 (Reuters) - Allogene Therapeutics Inc ALLO.O:ALLOGENE THERAPEUTICS INC - SELECTS STANDARD FC REGIMEN FOR ALPHA3 STUDY - SEC FILINGALLOGENE THERAPEUTICS INC - FC PLUS ALLO-647 ARM CLOSED DUE TO ADVERSE EVENT - SEC FILINGALLOGENE THERAPEUTICS INC: NONE OF CO'S TRIALS OPEN TO ENROLLMENT OR PIPELINE PROGRAMS INCLUDE ALLO-647ALLOGENE THERAPEUTICS: WILL ADVANCE NEXT-GENERATION ALLOCAR T PRODUCT CANDIDATES USING PROPRIETARY DAGGER PLATFORM TECHNOLOGYALLOGENE THERAPEUTICS: GRADE 5 ADVERSE EVENT IN FC PLUS ALLO-647 ARM ATTRIBUTED TO USE OF ALLO-647Source text: [ID:n0001193125-25-171091]Further company coverage: ALLO.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}